Cargando…
Nanocomposites as biomolecules delivery agents in nanomedicine
Nanoparticles (NPs) are atomic clusters of crystalline or amorphous structure that possess unique physical and chemical properties associated with a size range of between 1 and 100 nm. Their nano-sized dimensions, which are in the same range as those of vital biomolecules, such as antibodies, membra...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448271/ https://www.ncbi.nlm.nih.gov/pubmed/30943985 http://dx.doi.org/10.1186/s12951-019-0479-x |
_version_ | 1783408668182577152 |
---|---|
author | Bamburowicz-Klimkowska, Magdalena Poplawska, Magdalena Grudzinski, Ireneusz P. |
author_facet | Bamburowicz-Klimkowska, Magdalena Poplawska, Magdalena Grudzinski, Ireneusz P. |
author_sort | Bamburowicz-Klimkowska, Magdalena |
collection | PubMed |
description | Nanoparticles (NPs) are atomic clusters of crystalline or amorphous structure that possess unique physical and chemical properties associated with a size range of between 1 and 100 nm. Their nano-sized dimensions, which are in the same range as those of vital biomolecules, such as antibodies, membrane receptors, nucleic acids, and proteins, allow them to interact with different structures within living organisms. Because of these features, numerous nanoparticles are used in medicine as delivery agents for biomolecules. However, off-target drug delivery can cause serious side effects to normal tissues and organs. Considering this issue, it is essential to develop bioengineering strategies to significantly reduce systemic toxicity and improve therapeutic effect. In contrast to passive delivery, nanosystems enable to obtain enhanced therapeutic efficacy, decrease the possibility of drug resistance, and reduce side effects of “conventional” therapy in cancers. The present review provides an overview of the most recent (mostly last 3 years) achievements related to different biomolecules used to enable targeting capabilities of highly diverse nanoparticles. These include monoclonal antibodies, receptor-specific peptides or proteins, deoxyribonucleic acids, ribonucleic acids, [DNA/RNA] aptamers, and small molecules such as folates, and even vitamins or carbohydrates. |
format | Online Article Text |
id | pubmed-6448271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64482712019-04-15 Nanocomposites as biomolecules delivery agents in nanomedicine Bamburowicz-Klimkowska, Magdalena Poplawska, Magdalena Grudzinski, Ireneusz P. J Nanobiotechnology Review Nanoparticles (NPs) are atomic clusters of crystalline or amorphous structure that possess unique physical and chemical properties associated with a size range of between 1 and 100 nm. Their nano-sized dimensions, which are in the same range as those of vital biomolecules, such as antibodies, membrane receptors, nucleic acids, and proteins, allow them to interact with different structures within living organisms. Because of these features, numerous nanoparticles are used in medicine as delivery agents for biomolecules. However, off-target drug delivery can cause serious side effects to normal tissues and organs. Considering this issue, it is essential to develop bioengineering strategies to significantly reduce systemic toxicity and improve therapeutic effect. In contrast to passive delivery, nanosystems enable to obtain enhanced therapeutic efficacy, decrease the possibility of drug resistance, and reduce side effects of “conventional” therapy in cancers. The present review provides an overview of the most recent (mostly last 3 years) achievements related to different biomolecules used to enable targeting capabilities of highly diverse nanoparticles. These include monoclonal antibodies, receptor-specific peptides or proteins, deoxyribonucleic acids, ribonucleic acids, [DNA/RNA] aptamers, and small molecules such as folates, and even vitamins or carbohydrates. BioMed Central 2019-04-03 /pmc/articles/PMC6448271/ /pubmed/30943985 http://dx.doi.org/10.1186/s12951-019-0479-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Bamburowicz-Klimkowska, Magdalena Poplawska, Magdalena Grudzinski, Ireneusz P. Nanocomposites as biomolecules delivery agents in nanomedicine |
title | Nanocomposites as biomolecules delivery agents in nanomedicine |
title_full | Nanocomposites as biomolecules delivery agents in nanomedicine |
title_fullStr | Nanocomposites as biomolecules delivery agents in nanomedicine |
title_full_unstemmed | Nanocomposites as biomolecules delivery agents in nanomedicine |
title_short | Nanocomposites as biomolecules delivery agents in nanomedicine |
title_sort | nanocomposites as biomolecules delivery agents in nanomedicine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448271/ https://www.ncbi.nlm.nih.gov/pubmed/30943985 http://dx.doi.org/10.1186/s12951-019-0479-x |
work_keys_str_mv | AT bamburowiczklimkowskamagdalena nanocompositesasbiomoleculesdeliveryagentsinnanomedicine AT poplawskamagdalena nanocompositesasbiomoleculesdeliveryagentsinnanomedicine AT grudzinskiireneuszp nanocompositesasbiomoleculesdeliveryagentsinnanomedicine |